ADP 101
Alternative Names: ADP-101Latest Information Update: 03 Apr 2024
At a glance
- Originator Stanford University
- Developer Alladapt Immunotherapeutics
- Class Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Food hypersensitivity
Most Recent Events
- 23 Feb 2024 Adverse events and efficacy data from a phase-I/II trial in Food hypersensitivity presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 22 Nov 2023 ADP 101 receives Fast Track designation for Food hypersensitivity [PO,Powder] (In adolescents, In children, In adults) in USA
- 09 Nov 2023 Updated adverse events and efficacy data from a phase I/II Harmony trial in Food Hypersensitivity presented at the American College of Allergy, Asthma & Immunology (AAAAI-2023)